As a result, the muscles become weak when a person performs repeated physical movements. The disease is neither contagious nor inherited but it is often misunderstood as a psychological issue or ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized ...

Remegen Co. Ltd. emerged as a surprise challenger in the generalized myasthenia gravis space, unveiling positive phase III data of its China-approved lupus drug, telitacicept (RCT-18; Tai’ai), in the ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with ...

Carte­sian Ther­a­peu­tics said its au­tol­o­gous CAR-T ther­a­py has shown “sus­tained ben­e­fits” in peo­ple with a rare au­toim­mune dis­ease, ac­cord­ing to the lat­est ...

Some patients have follow-up data extending to 128 weeks. 1 b. QMG (Quantitative Myasthenia Gravis) is a 13-item assessment by a clinician that quantifies MG disease severity. The total QMG score ...

Some patients have follow-up data extending to 128 weeks. 1 b. QMG (Quantitative Myasthenia Gravis) is a 13-item assessment by a clinician that quantifies MG disease severity. The total QMG score ...

1 Antozzi, C et al., Long-Term Safety and Efficacy of Nipocalimab in Generalized Myasthenia Gravis: Vivacity-MG3 Open-Label Extension Phase Results. Abstract #022 for poster presentation at 2025 ...

anti-LRP4+) adults with generalised myasthenia gravis (gMG). 1, 2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL b and QMG c scores over 84 ...